Dexamethasone ODF is under clinical development by AcuCort and currently in Phase II for Allergies. According to GlobalData, Phase II drugs for Allergies have a 53% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Dexamethasone ODF’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Dexamethasone ODF overview

Dexamethasone (Zeqmelit) is a long-acting synthetic adrenocorticoid with intense anti-inflammatory activity and mineralocorticoid activity. It is formulated as orodispersible film for oral route of administration. Zeqmelit is indicated for the treatment of anti-inflammatory and immunosuppressive treatment among others cerebral edema secondary to brain tumors, neurosurgery, brain abscesses treatment of acute and severe asthma Initial treatment of acute and severe dermatological diseases Initial, autoimmune diseases, active rheumatoid arthritis Prophylaxis and nausea and vomiting induced by cytostatics within the framework of antiemetic, whooping cough allergic reactions, including acute allergic reactions treatment of coronavirus 2019 (COVID-19) in adults and young patients.

Dexa ODF is under development for the treatment of allergic reactions, croup in children and chemotherapy-induced nausea and vomiting. Dexa ODF is administered by oral route as a fast dissolving film. The drug candidate rapidly dissolving film containing glucocorticoid dexamethasone. It acts by targeting the glucocorticoid receptor.

AcuCort overview

AcuCort develops glucocorticoid dexamethasone films for the treatment of acute allergic conditions. The Company offers a dissolving oral film containing the glucocorticoid dexamethasone for treatment of acute allergic reactions, croup, and chemotherapy-induced nausea and vomiting. It is headquartered in Helsingborg, Sweden.

For a complete picture of Dexamethasone ODF’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.